Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 60

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 60
---
 22,994 |   |
| Total capitalization                                                                                                                     |     | $              |  18,594 |   |     |           |  22,994 |   |

The number of the Common Stock to be issued and
outstanding immediately after this offering as shown above assumes that all of the Common Stock offered hereby are sold, and is based
on 60,729,100 Common Stock issued and outstanding as of the date of this prospectus. This number excludes:

| ● | 4,270,000 Common Stock                                                                                                                
 issuable upon the exercise of options issued to directors, employees and consultants under our incentive option plan outstanding      
 as of such date, with the average exercise prices at $0.29 per share, of which options to purchase 3,347,500 Common Stock were vested 
 as of such date;                                                                                                                      |

| ● | 2,930,000 Common Stock reserved for future issuance under our 2021 Global Share Incentive Plan (2021). |

| ● | 6,372,265 Common Stock issuable upon the exercise of our outstanding warrants with the average exercise price of $1.16 per share, exercisable until December 31, 2026; |

<div align='center'>33

DILUTION</div>

If you purchase shares underlying the Units
offered by the Company in this Primary Offering, you may experience dilution to the extent of the difference between the price per share
you pay in this Primary Offering and the net tangible book value per share of our Common Stock immediately after this offering. The net
tangible book value of our Common Stock on June 30, 2025 was approximately $ 3.8 million, or approximately $0.06 per share. Net tangible
book value per share is equal to the amount of our total tangible assets, less total liabilities, divided by the aggregate number of
shares of our Common Stock outstanding.

After giving effect to the assumed sale by
us of 3,125,000 shares underlying the Units (assuming the sale of all securities offered hereby, at the fixed public offering price of
$3.20 per Unit, and assuming no exercise of the IPO Warrants issued in connection with this offering), our as adjusted net tangible book
value as of June 30, 2025 would have been approximately $8.2 million, or approximately $0.13 per share. This represents an immediate
increase in net tangible book value of approximately $0.07 per